Roivant Sciences Stock (NASDAQ:ROIV)
Previous Close
$11.47
52W Range
$8.73 - $13.05
50D Avg
$10.77
200D Avg
$11.25
Market Cap
$7.70B
Avg Vol (3M)
$6.61M
Beta
1.16
Div Yield
-
ROIV Company Profile
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
ROIV Performance
Peer Comparison
| Ticker | Company |
|---|---|
| RVMD | Revolution Medicines, Inc. |
| KRYS | Krystal Biotech, Inc. |
| BGNE | BeiGene, Ltd. |
| APLS | Apellis Pharmaceuticals, Inc. |
| DAWN | Day One Biopharmaceuticals, Inc. |
| PLRX | Pliant Therapeutics, Inc. |
| LYRA | Lyra Therapeutics, Inc. |
| SNDX | Syndax Pharmaceuticals, Inc. |
| BPMC | Blueprint Medicines Corporation |
| AKRO | Akero Therapeutics, Inc. |
| CGEM | Cullinan Oncology, Inc. |
| PHAT | Phathom Pharmaceuticals, Inc. |
| VRDN | Viridian Therapeutics, Inc. |
| INZY | Inozyme Pharma, Inc. |
| ASND | Ascendis Pharma A/S |